THYROID HORMONE REPLACEMENT REDUCES the RISK of CARDIOVASCULAR DISEASES in DIABETIC NEPHROPATHY PATIENTS with SUBCLINICAL HYPOTHYROIDISM

Changhwan Seo, Seonghun Kim, Misol Lee, Min Uk Cha, Hyoungnae Kim, Seohyun Park, Hae Ryong Yun, Jong Hyun Jhee, Youn Kyung Kee, SeungHyeok Han, TaeHyun Yoo, Shin-Wook Kang, Jung Tak Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Patients with diabetic nephropathy (DMN) have an increased risk of cardiovascular disease (CVD). However, strategies to reduce this risk are limited. Thyroid hormone replacement therapy (THRT) in patients with hypothyroidism has been shown to reduce several surrogate markers of CVD. Therefore, we performed a study to determine if THRT would reduce CVD risk in patients with subclinical hypothyroidism (SCH) and DMN. Methods: This was a retrospective, nonrandomized study of patients with type 2 diabetes, DMN, and SCH. Those with known thyroid dysfunction or taking THRT at baseline were excluded. Patients receiving THRT for at least 180 days were included in the THRT group, while the remaining patients were assigned to the non-THRT group. The primary outcome was CVD events, which included coronary syndrome, cerebrovascular events, and peripheral artery diseases. Results: Among the 257 patients, 83 (32.3%) were in the THRT group. The mean ages were 62.7 ± 12.3 and 66.8 ± 12.4 years in the THRT and non-THRT groups, respectively. The corresponding numbers of male patients were 32 (40.0%) and 94 (53.1%). During a mean follow-up of 38.0 ± 29.2 months, 98 CVD events were observed. Acute coronary syndrome and cerebrovascular event prevalence rates were lower in the THRT group than the non-THRT group, but there was no difference for peripheral artery diseases. Multivariate Cox analysis revealed that THRT was independently associated with a decreased CVD event risk. Conclusion: THRT may decrease the risk of CVD in DMN patients with SCH. Randomized trials are needed to verify this finding.

Original languageEnglish
Pages (from-to)265-272
Number of pages8
JournalEndocrine Practice
Volume24
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Hormone Replacement Therapy
Thyroid Hormones
Cardiovascular Diseases
Hypothyroidism
Peripheral Arterial Disease
Diabetic Nephropathies
Acute Coronary Syndrome
Type 2 Diabetes Mellitus
Thyroid Gland
Multivariate Analysis
Retrospective Studies
Biomarkers

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Seo, Changhwan ; Kim, Seonghun ; Lee, Misol ; Cha, Min Uk ; Kim, Hyoungnae ; Park, Seohyun ; Yun, Hae Ryong ; Jhee, Jong Hyun ; Kee, Youn Kyung ; Han, SeungHyeok ; Yoo, TaeHyun ; Kang, Shin-Wook ; Park, Jung Tak. / THYROID HORMONE REPLACEMENT REDUCES the RISK of CARDIOVASCULAR DISEASES in DIABETIC NEPHROPATHY PATIENTS with SUBCLINICAL HYPOTHYROIDISM. In: Endocrine Practice. 2018 ; Vol. 24, No. 3. pp. 265-272.
@article{23ab410db370449f93b6d0c27975bc05,
title = "THYROID HORMONE REPLACEMENT REDUCES the RISK of CARDIOVASCULAR DISEASES in DIABETIC NEPHROPATHY PATIENTS with SUBCLINICAL HYPOTHYROIDISM",
abstract = "Objective: Patients with diabetic nephropathy (DMN) have an increased risk of cardiovascular disease (CVD). However, strategies to reduce this risk are limited. Thyroid hormone replacement therapy (THRT) in patients with hypothyroidism has been shown to reduce several surrogate markers of CVD. Therefore, we performed a study to determine if THRT would reduce CVD risk in patients with subclinical hypothyroidism (SCH) and DMN. Methods: This was a retrospective, nonrandomized study of patients with type 2 diabetes, DMN, and SCH. Those with known thyroid dysfunction or taking THRT at baseline were excluded. Patients receiving THRT for at least 180 days were included in the THRT group, while the remaining patients were assigned to the non-THRT group. The primary outcome was CVD events, which included coronary syndrome, cerebrovascular events, and peripheral artery diseases. Results: Among the 257 patients, 83 (32.3{\%}) were in the THRT group. The mean ages were 62.7 ± 12.3 and 66.8 ± 12.4 years in the THRT and non-THRT groups, respectively. The corresponding numbers of male patients were 32 (40.0{\%}) and 94 (53.1{\%}). During a mean follow-up of 38.0 ± 29.2 months, 98 CVD events were observed. Acute coronary syndrome and cerebrovascular event prevalence rates were lower in the THRT group than the non-THRT group, but there was no difference for peripheral artery diseases. Multivariate Cox analysis revealed that THRT was independently associated with a decreased CVD event risk. Conclusion: THRT may decrease the risk of CVD in DMN patients with SCH. Randomized trials are needed to verify this finding.",
author = "Changhwan Seo and Seonghun Kim and Misol Lee and Cha, {Min Uk} and Hyoungnae Kim and Seohyun Park and Yun, {Hae Ryong} and Jhee, {Jong Hyun} and Kee, {Youn Kyung} and SeungHyeok Han and TaeHyun Yoo and Shin-Wook Kang and Park, {Jung Tak}",
year = "2018",
month = "3",
day = "1",
doi = "10.4158/EP-2017-0017",
language = "English",
volume = "24",
pages = "265--272",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "3",

}

THYROID HORMONE REPLACEMENT REDUCES the RISK of CARDIOVASCULAR DISEASES in DIABETIC NEPHROPATHY PATIENTS with SUBCLINICAL HYPOTHYROIDISM. / Seo, Changhwan; Kim, Seonghun; Lee, Misol; Cha, Min Uk; Kim, Hyoungnae; Park, Seohyun; Yun, Hae Ryong; Jhee, Jong Hyun; Kee, Youn Kyung; Han, SeungHyeok; Yoo, TaeHyun; Kang, Shin-Wook; Park, Jung Tak.

In: Endocrine Practice, Vol. 24, No. 3, 01.03.2018, p. 265-272.

Research output: Contribution to journalArticle

TY - JOUR

T1 - THYROID HORMONE REPLACEMENT REDUCES the RISK of CARDIOVASCULAR DISEASES in DIABETIC NEPHROPATHY PATIENTS with SUBCLINICAL HYPOTHYROIDISM

AU - Seo, Changhwan

AU - Kim, Seonghun

AU - Lee, Misol

AU - Cha, Min Uk

AU - Kim, Hyoungnae

AU - Park, Seohyun

AU - Yun, Hae Ryong

AU - Jhee, Jong Hyun

AU - Kee, Youn Kyung

AU - Han, SeungHyeok

AU - Yoo, TaeHyun

AU - Kang, Shin-Wook

AU - Park, Jung Tak

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: Patients with diabetic nephropathy (DMN) have an increased risk of cardiovascular disease (CVD). However, strategies to reduce this risk are limited. Thyroid hormone replacement therapy (THRT) in patients with hypothyroidism has been shown to reduce several surrogate markers of CVD. Therefore, we performed a study to determine if THRT would reduce CVD risk in patients with subclinical hypothyroidism (SCH) and DMN. Methods: This was a retrospective, nonrandomized study of patients with type 2 diabetes, DMN, and SCH. Those with known thyroid dysfunction or taking THRT at baseline were excluded. Patients receiving THRT for at least 180 days were included in the THRT group, while the remaining patients were assigned to the non-THRT group. The primary outcome was CVD events, which included coronary syndrome, cerebrovascular events, and peripheral artery diseases. Results: Among the 257 patients, 83 (32.3%) were in the THRT group. The mean ages were 62.7 ± 12.3 and 66.8 ± 12.4 years in the THRT and non-THRT groups, respectively. The corresponding numbers of male patients were 32 (40.0%) and 94 (53.1%). During a mean follow-up of 38.0 ± 29.2 months, 98 CVD events were observed. Acute coronary syndrome and cerebrovascular event prevalence rates were lower in the THRT group than the non-THRT group, but there was no difference for peripheral artery diseases. Multivariate Cox analysis revealed that THRT was independently associated with a decreased CVD event risk. Conclusion: THRT may decrease the risk of CVD in DMN patients with SCH. Randomized trials are needed to verify this finding.

AB - Objective: Patients with diabetic nephropathy (DMN) have an increased risk of cardiovascular disease (CVD). However, strategies to reduce this risk are limited. Thyroid hormone replacement therapy (THRT) in patients with hypothyroidism has been shown to reduce several surrogate markers of CVD. Therefore, we performed a study to determine if THRT would reduce CVD risk in patients with subclinical hypothyroidism (SCH) and DMN. Methods: This was a retrospective, nonrandomized study of patients with type 2 diabetes, DMN, and SCH. Those with known thyroid dysfunction or taking THRT at baseline were excluded. Patients receiving THRT for at least 180 days were included in the THRT group, while the remaining patients were assigned to the non-THRT group. The primary outcome was CVD events, which included coronary syndrome, cerebrovascular events, and peripheral artery diseases. Results: Among the 257 patients, 83 (32.3%) were in the THRT group. The mean ages were 62.7 ± 12.3 and 66.8 ± 12.4 years in the THRT and non-THRT groups, respectively. The corresponding numbers of male patients were 32 (40.0%) and 94 (53.1%). During a mean follow-up of 38.0 ± 29.2 months, 98 CVD events were observed. Acute coronary syndrome and cerebrovascular event prevalence rates were lower in the THRT group than the non-THRT group, but there was no difference for peripheral artery diseases. Multivariate Cox analysis revealed that THRT was independently associated with a decreased CVD event risk. Conclusion: THRT may decrease the risk of CVD in DMN patients with SCH. Randomized trials are needed to verify this finding.

UR - http://www.scopus.com/inward/record.url?scp=85044171371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044171371&partnerID=8YFLogxK

U2 - 10.4158/EP-2017-0017

DO - 10.4158/EP-2017-0017

M3 - Article

C2 - 29547051

AN - SCOPUS:85044171371

VL - 24

SP - 265

EP - 272

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 3

ER -